Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6468-6476

  Zhang, Peisheng ^a   Côté, Anik L ^a   De Vries, Victor C ^a   Usherwood, Edward J ^a   Turk, Mary Jo ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 100; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CANCER GROWTH; CANCER PREVENTION; CANCER SURGERY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOREGULATION; LYMPHOCYTE DEPLETION; MALE; MELANOCYTE; MELANOMA B16; MEMORY CELL; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; TUMOR RECURRENCE; VITILIGO;

ANIMALS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; POSTOPERATIVE PERIOD; T-LYMPHOCYTES; VITILIGO;

EID: 34447117554     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1264     Document Type: Article

References (50)

1. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957;18:769-78.
2. Bursuker I, North RJ. Immunological consequences of tumor excision: from active immunity to immunological memory. Int J Cancer 1986;37:275-81.
3. + T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006;211:214-24.
4. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200:771-82.
5. Romero P, Rod Dunbar P, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-50.
6. - effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002;62:1743-50.
7. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
8. + T cell responses. J Exp Med 2002;196:1585-92.
9. + T cell responses. J Exp Med 2003;198:889-901.
10. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003;198:1023-34.
11. + T cell immunity against B16 melanoma. J Immunol 2003;171:5940-7.
12. Luo Y, Zhou H, Mizutani M, et al. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res 2005;65:3419-27.
13. + T cells. J Exp Med 2003;198:569-80.
14. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001;61:1095-9.
15. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185:453-9.
16. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-86.
17. + T regulatory cells. J Immunol 2006;176:3301-5.
18. + T cell effector population size. J Immunol 2004;173:2923-7.
19. + T cell survival controlled by clonal abundance. Science 2006;312:114-6.
20. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005;102:9571-6.
21. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
22. + T cells. J Exp Med 2001;194:953-66.
23. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A 2004;101:16004-9.
24. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-34.
25. Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 2002;188:122-35.
26. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987;123:1053-5.
27. He H, Wisner P, Yang G, et al. Combined IL-21 and low-dose IL-2therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 2006;4:24.
28. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-66.
29. + T cells to the antitumor immune response. J Exp Med 2005;201:1591-602.
30. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8.
31. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-32.
32. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591-601.
33. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005;17:326-32.
34. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002;111:837-51.
35. + T cell contraction is controlled by early inflammation. Nat Immunol 2004;5:809-17.
36. Roberts AD, Ely KH, Woodland DL. Differential contributions of central and effector memory T cells to recall responses. J Exp Med 2005;202:123-33.
37. Obar JJ, Fuse S, Leung EK, Bellfy SC, Usherwood EJ. Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J Virol 2006;80:8303-15.
38. Tewari K, Sacha J, Gao X, Suresh M. Effect of chronic viral infection on epitope selection, cytokine production, and surface phenotype of CD8 T cells and the role of IFN-γ receptor in immune regulation. J Immunol 2004;172:1491-500.
39. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
40. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005;28:582-92.
41. Chace JH, Cowdery JS, Field EH. Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J Immunol 1994;152:405-12.
42. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-9.
43. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005;434:88-93.
44. + T cells after acute infection. Nat Immunol 2004;5:927-33.
45. Bursuker I, North R. Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 1984;159:1312-21.
46. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000;164:2214-20.
47. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004;64:2205-11.
48. + regulatory T cell proliferation. J Exp Med 2005;202:919-29.
49. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983;9:689-96.
50. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.